{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:12:04Z","timestamp":1793391124813,"version":"4.5.0"},"reference-count":251,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-024-00540-y","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T08:02:01Z","timestamp":1723622521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":175,"title":["Heart failure with preserved ejection fraction"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7063-1727","authenticated-orcid":false,"given":"Carine E.","family":"Hamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"DeJong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0356-1471","authenticated-orcid":false,"given":"Nick","family":"Hartshorne-Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5655-8201","authenticated-orcid":false,"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1903-0018","authenticated-orcid":false,"given":"Carolyn S. P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"540_CR1","unstructured":"Mann, D. L., Zipes, D. P., Libby, P. & Bonow, R. O. Braunwald\u2019s Heart Disease: A Textbook of Cardiovascular Medicine 10th edn (Elsevier\/Saunders, 2015)."},{"key":"540_CR2","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich, P. A. et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145, e895\u2013e1032 (2022). AHA\/ACC\/HFSA guidelines on the diagnosis and management of HF.","journal-title":"Circulation"},{"key":"540_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1046\/j.1365-2796.1997.129150000.x","volume":"241","author":"M Kupari","year":"1997","unstructured":"Kupari, M., Lindroos, M., Iivanainen, A. M., Heikkil\u00e4, J. & Tilvis, R. Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J. Intern. Med. 241, 387\u2013394 (1997).","journal-title":"J. Intern. Med."},{"key":"540_CR4","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1161\/01.CIR.98.21.2282","volume":"98","author":"M Senni","year":"1998","unstructured":"Senni, M. et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 98, 2282\u20132289 (1998).","journal-title":"Circulation"},{"key":"540_CR5","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1001\/jama.296.18.2209","volume":"296","author":"F Bursi","year":"2006","unstructured":"Bursi, F. et al. Systolic and diastolic heart failure in the community. JAMA 296, 2209\u20132216 (2006).","journal-title":"JAMA"},{"key":"540_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","volume":"355","author":"TE Owan","year":"2006","unstructured":"Owan, T. E. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 355, 251\u2013259 (2006).","journal-title":"N. Engl. J. Med."},{"key":"540_CR7","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0735-1097(99)00118-7","volume":"33","author":"RS Vasan","year":"1999","unstructured":"Vasan, R. S. et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J. Am. Coll. Cardiol. 33, 1948\u20131955 (1999).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR8","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0002-9149(00)01165-6","volume":"86","author":"RB Devereux","year":"2000","unstructured":"Devereux, R. B. et al. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am. J. Cardiol. 86, 1090\u20131096 (2000).","journal-title":"Am. J. Cardiol."},{"key":"540_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0002-9149(00)01393-X","volume":"87","author":"DW Kitzman","year":"2001","unstructured":"Kitzman, D. W. et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am. J. Cardiol. 87, 413\u2013419 (2001).","journal-title":"Am. J. Cardiol."},{"key":"540_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.7326\/0003-4819-137-8-200210150-00006","volume":"137","author":"JS Gottdiener","year":"2002","unstructured":"Gottdiener, J. S. et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann. Intern. Med. 137, 631\u2013639 (2002).","journal-title":"Ann. Intern. Med."},{"key":"540_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1056\/NEJMoa051530","volume":"355","author":"RS Bhatia","year":"2006","unstructured":"Bhatia, R. S. et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N. Engl. J. Med. 355, 260\u2013269 (2006).","journal-title":"N. Engl. J. Med."},{"key":"540_CR12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","volume":"362","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer, M. A. et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362, 759\u2013766 (2003).","journal-title":"Lancet"},{"key":"540_CR13","first-page":"352","volume":"23","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt, B. et al. Universal definition and classification of heart failure: a report of the heart failure society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J. Card. Fail. 23, 352\u2013380 (2021). Proposal for a universal definition of HF.","journal-title":"J. Card. Fail."},{"key":"540_CR14","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726 (2021). European Society of Cardiology guidelines on the diagnosis and management of HF.","journal-title":"Eur. Heart J."},{"key":"540_CR15","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson, M. M. et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 81, 1835\u20131878 (2023). ACC expert consensus document on the management of HFpEF.","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR16","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1093\/eurheartj\/ehaa158","volume":"41","author":"CSP Lam","year":"2020","unstructured":"Lam, C. S. P., Voors, A. A., Piotr, P., McMurray, J. J. V. & Solomon, S. D. Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. Eur. Heart J. 41, 2353\u20132355 (2020).","journal-title":"Eur. Heart J."},{"key":"540_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","volume":"19","author":"G Savarese","year":"2022","unstructured":"Savarese, G., Stolfo, D., Sinagra, G. & Lund, L. H. Heart failure with mid-range or mildly reduced ejection fraction. Nat. Rev. Cardiol. 19, 100\u2013116 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"540_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","volume":"37","author":"SD Solomon","year":"2016","unstructured":"Solomon, S. D. et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur. Heart J. 37, 455\u2013462 (2016).","journal-title":"Eur. Heart J."},{"key":"540_CR19","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1016\/j.jacc.2017.04.001","volume":"69","author":"D Kotecha","year":"2017","unstructured":"Kotecha, D. et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J. Am. Coll. Cardiol. 69, 2885\u20132896 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR20","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.1149","volume":"20","author":"LH Lund","year":"2018","unstructured":"Lund, L. H. et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur. J. Heart Fail. 20, 1230\u20131239 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR21","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/ejhf.1160","volume":"20","author":"AH Abdul-Rahim","year":"2018","unstructured":"Abdul-Rahim, A. H. et al. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. Eur. J. Heart Fail. 20, 1139\u20131145 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR22","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","volume":"141","author":"SD Solomon","year":"2020","unstructured":"Solomon, S. D. et al. Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. Circulation 141, 352\u2013361 (2020).","journal-title":"Circulation"},{"key":"540_CR23","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089\u20131098 (2022).","journal-title":"N. Engl. J. Med."},{"key":"540_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.005956","volume":"12","author":"WJ Paulus","year":"2019","unstructured":"Paulus, W. J. Phenotypic persistence in heart failure with preserved ejection fraction. Circ. Heart Fail. 12, e005956 (2019).","journal-title":"Circ. Heart Fail."},{"key":"540_CR25","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/ejhf.2470","volume":"24","author":"MS Khan","year":"2022","unstructured":"Khan, M. S., Shahid, I., Fonarow, G. C. & Greene, S. J. Classifying heart failure based on ejection fraction: imperfect but enduring. Eur. J. Heart Fail. 24, 1154\u20131157 (2022).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR26","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1161\/CIRCULATIONAHA.122.062022","volume":"146","author":"CSP Lam","year":"2022","unstructured":"Lam, C. S. P. & Solomon, S. D. DELIVERing therapeutic efficacy across the ejection fraction spectrum of heart failure. Circulation 146, 1193\u20131195 (2022).","journal-title":"Circulation"},{"key":"540_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/eurheartj\/ehab828","volume":"43","author":"T Kondo","year":"2021","unstructured":"Kondo, T. & McMurray, J. J. V. Re-emergence of heart failure with a normal ejection fraction? Eur. Heart J. 43, 427\u2013429 (2021).","journal-title":"Eur. Heart J."},{"key":"540_CR28","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators.","year":"2018","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.\u00a0Lancet 392, 1789\u20131858 (2018).","journal-title":"Lancet"},{"key":"540_CR29","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ejhf.1858","volume":"22","author":"A Groenewegen","year":"2020","unstructured":"Groenewegen, A., Rutten, F. H., Mosterd, A. & Hoes, A. W. Epidemiology of heart failure. Eur. J. Heart Fail. 22, 1342\u20131356 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR30","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1093\/eurheartj\/ehac248","volume":"43","author":"PM Becher","year":"2022","unstructured":"Becher, P. M., Lund, L. H., Coats, A. J. S. & Savarese, G. An update on global epidemiology in heart failure. Eur. Heart J. 43, 3005\u20133007 (2022).","journal-title":"Eur. Heart J."},{"key":"540_CR31","first-page":"1444","volume":"83","author":"MM Thomas","year":"2022","unstructured":"Thomas, M. M. et al. 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction. J. Am. Coll. Cardiol. 83, 1444\u20131488 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR32","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2023.03","volume":"9","author":"CJ Kapelios","year":"2023","unstructured":"Kapelios, C. J., Shahim, B., Lund, L. H. & Savarese, G. Epidemiology, clinical characteristics and cause-specific outcomes in heart failure with preserved ejection fraction. Card. Fail. Rev. 9, e14 (2023). 2023.","journal-title":"Card. Fail. Rev."},{"key":"540_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay, S. M., Roger, V. L. & Redfield, M. M. Epidemiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 14, 591\u2013602 (2017).","journal-title":"Nat. Rev. Cardiol."},{"key":"540_CR34","doi-asserted-by":"publisher","first-page":"e665","DOI":"10.1016\/S2214-109X(17)30196-1","volume":"5","author":"H Dokainish","year":"2017","unstructured":"Dokainish, H. et al. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob. Health 5, e665\u2013e672 (2017).","journal-title":"Lancet Glob. Health"},{"key":"540_CR35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1388-9842(02)00034-X","volume":"4","author":"F Ceia","year":"2002","unstructured":"Ceia, F. et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur. J. Heart Fail. 4, 531\u2013539 (2002).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1161\/CIRCULATIONAHA.111.080770","volume":"126","author":"BA Steinberg","year":"2012","unstructured":"Steinberg, B. A. et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126, 65\u201375 (2012).","journal-title":"Circulation"},{"key":"540_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11897-013-0155-7","volume":"10","author":"AA Oktay","year":"2013","unstructured":"Oktay, A. A., Rich, J. D. & Shah, S. J. The emerging epidemic of heart failure with preserved ejection fraction. Curr. Heart Fail. Rep. 10, 401\u2013410 (2013).","journal-title":"Curr. Heart Fail. Rep."},{"key":"540_CR38","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.cardfail.2010.06.413","volume":"16","author":"K Nochioka","year":"2010","unstructured":"Nochioka, K., Shiba, N., Kohno, H., Miura, M. & Shimokawa, H. Both high and low body mass indexes are prognostic risks in Japanese patients with chronic heart failure: implications from the CHART study. J. Card. Fail. 16, 880\u2013887 (2010).","journal-title":"J. Card. Fail."},{"key":"540_CR39","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1253\/circj.CJ-11-0135","volume":"75","author":"N Shiba","year":"2011","unstructured":"Shiba, N., Nochioka, K., Miura, M., Kohno, H. & Shimokawa, H. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan \u2014 first report from the CHART-2 study. Circ. J. 75, 823\u2013833 (2011).","journal-title":"Circ. J."},{"key":"540_CR40","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s11897-014-0220-x","volume":"11","author":"SM Dunlay","year":"2014","unstructured":"Dunlay, S. M. & Roger, V. L. Understanding the epidemic of heart failure: past, present, future. Curr. Heart Fail. Rep. 11, 404\u2013415 (2014).","journal-title":"Curr. Heart Fail. Rep."},{"key":"540_CR41","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","volume":"17","author":"BA Borlaug","year":"2020","unstructured":"Borlaug, B. A. Evaluation and management of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 17, 559\u2013573 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"540_CR42","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","volume":"29","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt, B. et al. Heart failure epidemiology and outcomes statistics: a report of the heart failure society of America. J. Card. Fail. 29, 1412\u20131451 (2023). Report from the HFSA providing trends in the epidemiology and outcomes of HF.","journal-title":"J. Card. Fail."},{"key":"540_CR43","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jacc.2021.10.043","volume":"79","author":"RS Vasan","year":"2022","unstructured":"Vasan, R. S., Enserro, D. M., Beiser, A. S. & Xanthakis, V. Lifetime risk of heart failure among participants in the framingham study. J. Am. Coll. Cardiol. 79, 250\u2013263 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR44","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.003116","volume":"9","author":"JE Ho","year":"2016","unstructured":"Ho, J. E. et al. Predicting heart failure with preserved and reduced ejection fraction. Circ. Heart Fail. 9, e003116 (2016).","journal-title":"Circ. Heart Fail."},{"key":"540_CR45","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","volume":"175","author":"Y Gerber","year":"2015","unstructured":"Gerber, Y. et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern. Med. 175, 996\u20131004 (2015).","journal-title":"JAMA Intern. Med."},{"key":"540_CR46","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.jacc.2016.08.048","volume":"68","author":"D Kotecha","year":"2016","unstructured":"Kotecha, D. et al. Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J. Am. Coll. Cardiol. 68, 2217\u20132228 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR47","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jchf.2016.10.005","volume":"5","author":"CS Lam","year":"2017","unstructured":"Lam, C. S. et al. Atrial fibrillation in heart failure with preserved ejection fraction: association with exercise capacity, left ventricular filling pressures, natriuretic peptides, and left atrial volume. JACC Heart Fail. 5, 92\u201398 (2017).","journal-title":"JACC Heart Fail."},{"key":"540_CR48","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.115.018614","volume":"133","author":"R Santhanakrishnan","year":"2016","unstructured":"Santhanakrishnan, R. et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 133, 484\u2013492 (2016).","journal-title":"Circulation"},{"key":"540_CR49","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.113.001475","volume":"128","author":"R Zakeri","year":"2013","unstructured":"Zakeri, R., Chamberlain, A. M., Roger, V. L. & Redfield, M. M. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 128, 1085\u20131093 (2013).","journal-title":"Circulation"},{"key":"540_CR50","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jchf.2017.05.001","volume":"5","author":"U Sartipy","year":"2017","unstructured":"Sartipy, U., Dahlstr\u00f6m, U., Fu, M. & Lund, L. H. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail. 5, 565\u2013574 (2017).","journal-title":"JACC Heart Fail."},{"key":"540_CR51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCULATIONAHA.119.042996","volume":"141","author":"M Packer","year":"2020","unstructured":"Packer, M., Lam, C. S. P., Lund, L. H. & Redfield, M. M. Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy. Circulation 141, 4\u20136 (2020).","journal-title":"Circulation"},{"key":"540_CR52","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/ejhf.1091","volume":"20","author":"V Bhambhani","year":"2018","unstructured":"Bhambhani, V. et al. Predictors and outcomes of heart failure with mid-range ejection fraction. Eur. J. Heart Fail. 20, 651\u2013659 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR53","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jchf.2018.05.018","volume":"6","author":"N Savji","year":"2018","unstructured":"Savji, N. et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Fail. 6, 701\u2013709 (2018).","journal-title":"JACC Heart Fail."},{"key":"540_CR54","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/ejhf.2563","volume":"24","author":"H Sorimachi","year":"2022","unstructured":"Sorimachi, H. et al. Sex and central obesity in heart failure with preserved ejection fraction. Eur. J. Heart Fail. 24, 1359\u20131370 (2022).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR55","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jchf.2018.09.006","volume":"6","author":"A Pandey","year":"2018","unstructured":"Pandey, A. et al. Physical activity, fitness, and obesity in heart failure with preserved ejection fraction. JACC Heart Fail. 6, 975\u2013982 (2018).","journal-title":"JACC Heart Fail."},{"key":"540_CR56","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.003875","volume":"10","author":"O Vedin","year":"2017","unstructured":"Vedin, O. et al. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ. Heart Fail. 10, e003875 (2017).","journal-title":"Circ. Heart Fail."},{"key":"540_CR57","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1093\/eurheartj\/ehy531","volume":"39","author":"SJ Shah","year":"2018","unstructured":"Shah, S. J. et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur. Heart J. 39, 3439\u20133450 (2018).","journal-title":"Eur. Heart J."},{"key":"540_CR58","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1161\/CIRCULATIONAHA.119.042569","volume":"140","author":"J Tromp","year":"2019","unstructured":"Tromp, J. et al. Biomarker correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction. Circulation 140, 1359\u20131361 (2019).","journal-title":"Circulation"},{"key":"540_CR59","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/ejhf.2408","volume":"24","author":"A Kap\u0142on-Cie\u015blicka","year":"2022","unstructured":"Kap\u0142on-Cie\u015blicka, A. et al. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction \u2014 insights from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur. J. Heart Fail. 24, 335\u2013350 (2022).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR60","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/ejhf.945","volume":"19","author":"AS Koh","year":"2017","unstructured":"Koh, A. S. et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur. J. Heart Fail. 19, 1624\u20131634 (2017).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR61","doi-asserted-by":"publisher","first-page":"100705","DOI":"10.1016\/j.xkme.2023.100705","volume":"5","author":"RN Patel","year":"2023","unstructured":"Patel, R. N., Sharma, A., Prasad, A. & Bansal, S. Heart failure with preserved ejection fraction with CKD: a narrative review of a multispecialty disorder. Kidney Med. 5, 100705 (2023).","journal-title":"Kidney Med."},{"key":"540_CR62","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/eurheartj\/eht066","volume":"34","author":"FP Brouwers","year":"2013","unstructured":"Brouwers, F. P. et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur. Heart J. 34, 1424\u20131431 (2013).","journal-title":"Eur. Heart J."},{"key":"540_CR63","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ejhf.497","volume":"18","author":"JM ter Maaten","year":"2016","unstructured":"ter Maaten, J. M. et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur. J. Heart Fail. 18, 588\u2013598 (2016).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR64","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/ejhf.1585","volume":"21","author":"J Tromp","year":"2019","unstructured":"Tromp, J. et al. Heart failure around the world. Eur. J. Heart Fail. 21, 1187\u20131196 (2019).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR65","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007901","volume":"14","author":"J Tromp","year":"2021","unstructured":"Tromp, J. et al. Global differences in heart failure with preserved ejection fraction. Circ. Heart Fail. 14, e007901 (2021).","journal-title":"Circ. Heart Fail."},{"key":"540_CR66","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00392-019-01430-0","volume":"108","author":"C Ergatoudes","year":"2019","unstructured":"Ergatoudes, C. et al. Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure Registry. Clin. Res. Cardiol. 108, 1025\u20131033 (2019).","journal-title":"Clin. Res. Cardiol."},{"key":"540_CR67","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V. & Borlaug, B. A. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 136, 6\u201319 (2017).","journal-title":"Circulation"},{"key":"540_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002541","volume":"15","author":"J Tromp","year":"2018","unstructured":"Tromp, J. et al. Multimorbidity in patients with heart failure from 11 Asian regions: a prospective cohort study using the ASIAN-HF registry. PLoS Med. 15, e1002541 (2018).","journal-title":"PLoS Med."},{"key":"540_CR69","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/S0735-1097(23)01088-4","volume":"81","author":"JJV McMurray","year":"2023","unstructured":"McMurray, J. J. V. et al. Geographical variation in patient characteristics and outcomes in HFPEF. J. Am. Coll. Cardiol. 81, 644\u2013644 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR70","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.122.062832","volume":"147","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Sex differences in characteristics, outcomes, and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: insights from DAPA-HF and DELIVER. Circulation 147, 624\u2013634 (2023).","journal-title":"Circulation"},{"key":"540_CR71","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1161\/CIRCHEARTFAILURE.112.970061","volume":"5","author":"CS Lam","year":"2012","unstructured":"Lam, C. S. et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ. Heart Fail. 5, 571\u2013578 (2012).","journal-title":"Circ. Heart Fail."},{"key":"540_CR72","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1093\/eurheartj\/ehz835","volume":"40","author":"CSP Lam","year":"2019","unstructured":"Lam, C. S. P. et al. Sex differences in heart failure. Eur. Heart J. 40, 3859\u20133868c (2019).","journal-title":"Eur. Heart J."},{"key":"540_CR73","doi-asserted-by":"publisher","first-page":"m2688","DOI":"10.1136\/bmj.m2688","volume":"370","author":"NS Shah","year":"2020","unstructured":"Shah, N. S. et al. Heterogeneous trends in burden of heart disease mortality by subtypes in the United States, 1999-2018: observational analysis of vital statistics. BMJ 370, m2688 (2020).","journal-title":"BMJ"},{"key":"540_CR74","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/jamacardio.2024.0615","volume":"9","author":"A Sayed","year":"2024","unstructured":"Sayed, A. et al. Reversals in the decline of heart failure mortality in the US, 1999 to 2021. JAMA Cardiol. 9, 585\u2013589 (2024).","journal-title":"JAMA Cardiol."},{"key":"540_CR75","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1161\/CIRCULATIONAHA.108.815944","volume":"119","author":"DS Lee","year":"2009","unstructured":"Lee, D. S. et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation 119, 3070\u20133077 (2009).","journal-title":"Circulation"},{"key":"540_CR76","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/eurheartj\/ehm554","volume":"29","author":"C Tribouilloy","year":"2008","unstructured":"Tribouilloy, C. et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur. Heart J. 29, 339\u2013347 (2008).","journal-title":"Eur. Heart J."},{"key":"540_CR77","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","volume":"33","author":"Meta-analysis Global Group in Chronic Heart Failure (MAGGIC).","year":"2012","unstructured":"Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis.\u00a0Eur. Heart J. 33, 1750\u20131757 (2012).","journal-title":"Eur. Heart J."},{"key":"540_CR78","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/eurheartj\/ehy005","volume":"39","author":"CSP Lam","year":"2018","unstructured":"Lam, C. S. P. et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur. Heart J. 39, 1770\u20131780 (2018).","journal-title":"Eur. Heart J."},{"key":"540_CR79","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451\u20131461 (2021). Clinical trial of the effects of empagliflozin on individuals with HFpEF.","journal-title":"N. Engl. J. Med."},{"key":"540_CR80","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413\u20131424 (2020).","journal-title":"N. Engl. J. Med."},{"key":"540_CR81","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995\u20132008 (2019).","journal-title":"N. Engl. J. Med."},{"key":"540_CR82","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1161\/CIRCHEARTFAILURE.107.743146","volume":"1","author":"DM Henkel","year":"2008","unstructured":"Henkel, D. M., Redfield, M. M., Weston, S. A., Gerber, Y. & Roger, V. L. Death in heart failure: a community perspective. Circ. Heart Fail. 1, 91\u201397 (2008).","journal-title":"Circ. Heart Fail."},{"key":"540_CR83","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jacc.2016.10.078","volume":"69","author":"M Vaduganathan","year":"2017","unstructured":"Vaduganathan, M. et al. Mode of death in heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 69, 556\u2013569 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR84","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ijcard.2016.11.154","volume":"228","author":"S Aschauer","year":"2017","unstructured":"Aschauer, S. et al. Modes of death in patients with heart failure and preserved ejection fraction. Int. J. Cardiol. 228, 422\u2013426 (2017).","journal-title":"Int. J. Cardiol."},{"key":"540_CR85","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf, S. et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362, 777\u2013781 (2003).","journal-title":"Lancet"},{"key":"540_CR86","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1161\/CIRCULATIONAHA.109.909614","volume":"121","author":"MR Zile","year":"2010","unstructured":"Zile, M. R. et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) trial. Circulation 121, 1393\u20131405 (2010).","journal-title":"Circulation"},{"key":"540_CR87","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie, B. M. et al. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 359, 2456\u20132467 (2008).","journal-title":"N. Engl. J. Med."},{"key":"540_CR88","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt, B. et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370, 1383\u20131392 (2014).","journal-title":"N. Engl. J. Med."},{"key":"540_CR89","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1161\/CIRCULATIONAHA.106.628347","volume":"114","author":"A Ahmed","year":"2006","unstructured":"Ahmed, A. et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 114, 397\u2013403 (2006).","journal-title":"Circulation"},{"key":"540_CR90","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijcard.2014.02.018","volume":"173","author":"M Senni","year":"2014","unstructured":"Senni, M. et al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Int. J. Cardiol. 173, 163\u2013169 (2014).","journal-title":"Int. J. Cardiol."},{"key":"540_CR91","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.amjcard.2015.07.018","volume":"116","author":"GA Nichols","year":"2015","unstructured":"Nichols, G. A., Reynolds, K., Kimes, T. M., Rosales, A. G. & Chan, W. W. Comparison of risk of re-hospitalization, all-cause mortality, and medical care resource utilization in patients with heart failure and preserved versus reduced ejection fraction. Am. J. Cardiol. 116, 1088\u20131092 (2015).","journal-title":"Am. J. Cardiol."},{"key":"540_CR92","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.jacc.2009.08.019","volume":"54","author":"SM Dunlay","year":"2009","unstructured":"Dunlay, S. M. et al. Hospitalizations after heart failure diagnosis a community perspective. J. Am. Coll. Cardiol. 54, 1695\u20131702 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR93","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/ejhf.29","volume":"16","author":"JK Rogers","year":"2014","unstructured":"Rogers, J. K. et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur. J. Heart Fail. 16, 33\u201340 (2014).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR94","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","volume":"131","author":"SJ Shah","year":"2015","unstructured":"Shah, S. J. et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131, 269\u2013279 (2015).","journal-title":"Circulation"},{"key":"540_CR95","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-med-042220-022745","volume":"73","author":"K Omote","year":"2022","unstructured":"Omote, K., Verbrugge, F. H. & Borlaug, B. A. Heart failure with preserved ejection fraction: mechanisms and treatment strategies. Annu. Rev. Med. 73, 321\u2013337 (2022).","journal-title":"Annu. Rev. Med."},{"key":"540_CR96","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1161\/CIRCHEARTFAILURE.109.930701","volume":"3","author":"BA Borlaug","year":"2010","unstructured":"Borlaug, B. A., Nishimura, R. A., Sorajja, P., Lam, C. S. & Redfield, M. M. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ. Heart Fail. 3, 588\u2013595 (2010).","journal-title":"Circ. Heart Fail."},{"key":"540_CR97","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1093\/eurheartj\/ehz713","volume":"40","author":"YNV Reddy","year":"2019","unstructured":"Reddy, Y. N. V. et al. The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction. Eur. Heart J. 40, 3721\u20133730 (2019).","journal-title":"Eur. Heart J."},{"key":"540_CR98","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/hrt.2010.212787","volume":"97","author":"BA Borlaug","year":"2011","unstructured":"Borlaug, B. A. et al. Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart 97, 964\u2013969 (2011).","journal-title":"Heart"},{"key":"540_CR99","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","volume":"8","author":"VS Hahn","year":"2020","unstructured":"Hahn, V. S. et al. Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail. 8, 712\u2013724 (2020).","journal-title":"JACC Heart Fail."},{"key":"540_CR100","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1161\/CIRCHEARTFAILURE.113.000854","volume":"7","author":"MA Burke","year":"2014","unstructured":"Burke, M. A. et al. Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ. Heart Fail. 7, 288\u2013299 (2014).","journal-title":"Circ. Heart Fail."},{"key":"540_CR101","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.111.076075","volume":"126","author":"LV Heerebeek","year":"2012","unstructured":"Heerebeek, L. V. et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 126, 830\u2013839 (2012).","journal-title":"Circulation"},{"key":"540_CR102","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jacc.2013.09.052","volume":"63","author":"E Kraigher-Krainer","year":"2014","unstructured":"Kraigher-Krainer, E. et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 63, 447\u2013456 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR103","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jacc.2009.05.013","volume":"54","author":"BA Borlaug","year":"2009","unstructured":"Borlaug, B. A., Lam, C. S., Roger, V. L., Rodeheffer, R. J. & Redfield, M. M. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 54, 410\u2013418 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR104","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1161\/01.CIR.24.3.633","volume":"24","author":"E Braunwald","year":"1961","unstructured":"Braunwald, E. & Frahm, C. J. Studies on Starling\u2019s law of the heart: IV. Observations on the hemodynamic functions of the left atrium in man. Circulation 24, 633\u2013642 (1961).","journal-title":"Circulation"},{"key":"540_CR105","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1161\/CIRCHEARTFAILURE.114.001667","volume":"8","author":"V Melenovsky","year":"2015","unstructured":"Melenovsky, V. et al. Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Circ. Heart Fail. 8, 295\u2013303 (2015).","journal-title":"Circ. Heart Fail."},{"key":"540_CR106","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/CIRCIMAGING.108.813071","volume":"2","author":"M Kurt","year":"2009","unstructured":"Kurt, M., Wang, J., Torre-Amione, G. & Nagueh, S. F. Left atrial function in diastolic heart failure. Circ. Cardiovasc. Imaging 2, 10\u201315 (2009).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"540_CR107","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.1464","volume":"21","author":"YNV Reddy","year":"2019","unstructured":"Reddy, Y. N. V. et al. Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction. Eur. J. Heart Fail. 21, 891\u2013900 (2019).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR108","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.jacc.2020.07.009","volume":"76","author":"YNV Reddy","year":"2020","unstructured":"Reddy, Y. N. V., Obokata, M., Verbrugge, F. H., Lin, G. & Borlaug, B. A. Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation. J. Am. Coll. Cardiol. 76, 1051\u20131064 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR109","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","volume":"53","author":"CS Lam","year":"2009","unstructured":"Lam, C. S. et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J. Am. Coll. Cardiol. 53, 1119\u20131126 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR110","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/CIRCHEARTFAILURE.110.958801","volume":"4","author":"T Thenappan","year":"2011","unstructured":"Thenappan, T. et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ. Heart Fail. 4, 257\u2013265 (2011).","journal-title":"Circ. Heart Fail."},{"key":"540_CR111","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jacc.2020.06.069","volume":"76","author":"M Guazzi","year":"2020","unstructured":"Guazzi, M., Ghio, S. & Adir, Y. Pulmonary hypertension in HFpEF and HFrEF. J. Am. Coll. Cardiol. 76, 1102\u20131111 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR112","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamacardio.2018.0128","volume":"3","author":"RR Vanderpool","year":"2018","unstructured":"Vanderpool, R. R., Saul, M., Nouraie, M., Gladwin, M. T. & Simon, M. A. Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol. 3, 298\u2013306 (2018).","journal-title":"JAMA Cardiol."},{"key":"540_CR113","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1093\/eurheartj\/ehu193","volume":"35","author":"V Melenovsky","year":"2014","unstructured":"Melenovsky, V., Hwang, S. J., Lin, G., Redfield, M. M. & Borlaug, B. A. Right heart dysfunction in heart failure with preserved ejection fraction. Eur. Heart J. 35, 3452\u20133462 (2014).","journal-title":"Eur. Heart J."},{"key":"540_CR114","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","volume":"40","author":"M Obokata","year":"2019","unstructured":"Obokata, M., Reddy, Y. N. V., Melenovsky, V., Pislaru, S. & Borlaug, B. A. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur. Heart J. 40, 689\u2013697 (2019).","journal-title":"Eur. Heart J."},{"key":"540_CR115","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/ejhf.2929","volume":"25","author":"M Adamo","year":"2023","unstructured":"Adamo, M. et al. Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: an analysis from the ESC-HFA heart failure long-term registry. Eur. J. Heart Fail. 25, 1061\u20131071 (2023).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR116","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006331","volume":"13","author":"S Sarma","year":"2020","unstructured":"Sarma, S. et al. Mechanisms of chronotropic incompetence in heart failure with preserved ejection fraction. Circ. Heart Fail. 13, e006331 (2020).","journal-title":"Circ. Heart Fail."},{"key":"540_CR117","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1161\/CIRCULATIONAHA.106.632745","volume":"114","author":"BA Borlaug","year":"2006","unstructured":"Borlaug, B. A. et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 114, 2138\u20132147 (2006).","journal-title":"Circulation"},{"key":"540_CR118","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1161\/CIRCHEARTFAILURE.109.877720","volume":"3","author":"TT Phan","year":"2010","unstructured":"Phan, T. T. et al. Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ. Heart Fail. 3, 29\u201334 (2010).","journal-title":"Circ. Heart Fail."},{"key":"540_CR119","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1001\/jamacardio.2023.5500","volume":"9","author":"P Palau","year":"2024","unstructured":"Palau, P. et al. \u03b2-Blocker withdrawal and functional capacity improvement in patients with heart failure with preserved ejection fraction. JAMA Cardiol. 9, 392\u2013396 (2024).","journal-title":"JAMA Cardiol."},{"key":"540_CR120","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jchf.2023.09.007","volume":"12","author":"A Peikert","year":"2024","unstructured":"Peikert, A. et al. Contemporary use and implications of beta-blockers in patients with HFmrEF or HFpEF: the DELIVER trial. JACC Heart Fail. 12, 631\u2013644 (2024).","journal-title":"JACC Heart Fail."},{"key":"540_CR121","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/gerona\/gls099","volume":"68","author":"MJ Haykowsky","year":"2013","unstructured":"Haykowsky, M. J. et al. Relationship of flow-mediated arterial dilation and exercise capacity in older patients with heart failure and preserved ejection fraction. J. Gerontol. A Biol. Sci. Med. Sci. 68, 161\u2013167 (2013).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"540_CR122","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cardfail.2015.09.003","volume":"22","author":"S Mar\u00e9chaux","year":"2016","unstructured":"Mar\u00e9chaux, S. et al. Vascular and microvascular endothelial function in heart failure with preserved ejection fraction. J. Card. Fail. 22, 3\u201311 (2016).","journal-title":"J. Card. Fail."},{"key":"540_CR123","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1161\/CIRCHEARTFAILURE.112.968594","volume":"5","author":"SF Mohammed","year":"2012","unstructured":"Mohammed, S. F. et al. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ. Heart Fail. 5, 710\u2013719 (2012).","journal-title":"Circ. Heart Fail."},{"key":"540_CR124","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jacc.2017.05.029","volume":"70","author":"YNV Reddy","year":"2017","unstructured":"Reddy, Y. N. V. et al. Arterial stiffening with exercise in patients with heart failure and preserved ejection fraction. J. Am. Coll. Cardiol. 70, 136\u2013148 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR125","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","volume":"131","author":"SF Mohammed","year":"2015","unstructured":"Mohammed, S. F. et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 131, 550\u2013559 (2015).","journal-title":"Circulation"},{"key":"540_CR126","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus, W. J. & Tsch\u00f6pe, C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 62, 263\u2013271 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR127","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1161\/CIRCHEARTFAILURE.109.931451","volume":"4","author":"D Westermann","year":"2011","unstructured":"Westermann, D. et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ. Heart Fail. 4, 44\u201352 (2011).","journal-title":"Circ. Heart Fail."},{"key":"540_CR128","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jacc.2019.12.069","volume":"75","author":"JA Chirinos","year":"2020","unstructured":"Chirinos, J. A. et al. Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction. J. Am. Coll. Cardiol. 75, 1281\u20131295 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR129","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/ejhf.1902","volume":"22","author":"M Packer","year":"2020","unstructured":"Packer, M., Lam, C. S. P., Lund, L. H., Maurer, M. S. & Borlaug, B. A. Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. Eur. J. Heart Fail. 22, 1551\u20131567 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR130","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/ejhf.2156","volume":"23","author":"J Tromp","year":"2021","unstructured":"Tromp, J. et al. Epicardial fat in heart failure with reduced versus preserved ejection fraction. Eur. J. Heart Fail. 23, 835\u2013838 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR131","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/ejhf.2337","volume":"23","author":"NR Pugliese","year":"2021","unstructured":"Pugliese, N. R. et al. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur. J. Heart Fail. 23, 1858\u20131871 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR132","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1002\/ejhf.2363","volume":"23","author":"J Tromp","year":"2021","unstructured":"Tromp, J., Packer, M. & Lam, C. S. The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal. Eur. J. Heart Fail. 23, 1872\u20131874 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR133","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.jacc.2016.12.033","volume":"69","author":"\u00c4 Mantel","year":"2017","unstructured":"Mantel, \u00c4., Holmqvist, M., Andersson, D. C., Lund, L. H. & Askling, J. Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure. J. Am. Coll. Cardiol. 69, 1275\u20131285 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR134","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ejhf.113","volume":"16","author":"U Khalid","year":"2014","unstructured":"Khalid, U. et al. Psoriasis and risk of heart failure: a nationwide cohort study. Eur. J. Heart Fail. 16, 743\u2013748 (2014).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR135","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ahj.2023.02.001","volume":"259","author":"J Fax\u00e9n","year":"2023","unstructured":"Fax\u00e9n, J. et al. Associations between rheumatoid arthritis, incident heart failure, and left ventricular ejection fraction. Am. Heart J. 259, 42\u201351 (2023).","journal-title":"Am. Heart J."},{"key":"540_CR136","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.3390\/cells11101657","volume":"11","author":"JC Bachmann","year":"2022","unstructured":"Bachmann, J. C. et al. Fibrotic signaling in cardiac fibroblasts and vascular smooth muscle cells: the dual roles of fibrosis in HFpEF and CAD. Cells 11, 1657 (2022).","journal-title":"Cells"},{"key":"540_CR137","doi-asserted-by":"publisher","first-page":"153633","DOI":"10.1016\/j.phymed.2021.153633","volume":"91","author":"Y Huang","year":"2021","unstructured":"Huang, Y. et al. An herbal preparation ameliorates heart failure with preserved ejection fraction by alleviating microvascular endothelial inflammation and activating NO-cGMP-PKG pathway. Phytomedicine 91, 153633 (2021).","journal-title":"Phytomedicine"},{"key":"540_CR138","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","volume":"4","author":"C Franssen","year":"2016","unstructured":"Franssen, C. et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail. 4, 312\u2013324 (2016).","journal-title":"JACC Heart Fail."},{"key":"540_CR139","doi-asserted-by":"publisher","first-page":"46","DOI":"10.14336\/AD.2022.0523","volume":"14","author":"Z Cai","year":"2023","unstructured":"Cai, Z. et al. The NO-cGMP-PKG axis in HFpEF: from pathological mechanisms to potential therapies. Aging Dis. 14, 46\u201362 (2023).","journal-title":"Aging Dis."},{"key":"540_CR140","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","volume":"568","author":"GG Schiattarella","year":"2019","unstructured":"Schiattarella, G. G. et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature 568, 351\u2013356 (2019).","journal-title":"Nature"},{"key":"540_CR141","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/01.CIR.0000155257.33485.6D","volume":"111","author":"A Borb\u00e9ly","year":"2005","unstructured":"Borb\u00e9ly, A. et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 111, 774\u2013781 (2005).","journal-title":"Circulation"},{"key":"540_CR142","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1161\/CIRCULATIONAHA.105.587519","volume":"113","author":"LV Heerebeek","year":"2006","unstructured":"Heerebeek, L. V. et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 113, 1966\u20131973 (2006).","journal-title":"Circulation"},{"key":"540_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19766-5","volume":"12","author":"L Schulz","year":"2022","unstructured":"Schulz, L. et al. Tubulin expression and modification in heart failure with preserved ejection fraction (HFpEF). Sci. Rep. 12, 15734 (2022).","journal-title":"Sci. Rep."},{"key":"540_CR144","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jacc.2009.05.012","volume":"54","author":"TT Phan","year":"2009","unstructured":"Phan, T. T. et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J. Am. Coll. Cardiol. 54, 402\u2013409 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR145","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1093\/cvr\/cvac179","volume":"118","author":"AE Peters","year":"2023","unstructured":"Peters, A. E. et al. Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions. Cardiovasc. Res. 118, 3403\u20133415 (2023).","journal-title":"Cardiovasc. Res."},{"key":"540_CR146","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.004962","volume":"11","author":"SD Solomon","year":"2018","unstructured":"Solomon, S. D. et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circ. Heart Fail. 11, e004962 (2018).","journal-title":"Circ. Heart Fail."},{"key":"540_CR147","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ejhf.110","volume":"16","author":"EE van Riet","year":"2014","unstructured":"van Riet, E. E. et al. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur. J. Heart Fail. 16, 772\u2013777 (2014).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR148","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.hfc.2018.08.002","volume":"15","author":"A Tibrewala","year":"2019","unstructured":"Tibrewala, A. & Yancy, C. W. Heart failure with preserved ejection fraction in women. Heart Fail. Clin. 15, 9\u201318 (2019).","journal-title":"Heart Fail. Clin."},{"key":"540_CR149","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jchf.2023.03.011","volume":"11","author":"AS Desai","year":"2023","unstructured":"Desai, A. S., Lam, C. S. P., McMurray, J. J. V. & Redfield, M. M. How to manage heart failure with preserved ejection fraction: practical guidance for clinicians. JACC Heart Fail. 11, 619\u2013636 (2023).","journal-title":"JACC Heart Fail."},{"key":"540_CR150","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/ejhf.2946","volume":"25","author":"KF Docherty","year":"2023","unstructured":"Docherty, K. F. et al. Heart failure diagnosis in the general community \u2014 who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur. J. Heart Fail. 25, 1185\u20131198 (2023).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR151","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","volume":"329","author":"MM Redfield","year":"2023","unstructured":"Redfield, M. M. & Borlaug, B. A. Heart failure with preserved ejection fraction: a review. JAMA 329, 827\u2013838 (2023).","journal-title":"JAMA"},{"key":"540_CR152","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","volume":"138","author":"YNV Reddy","year":"2018","unstructured":"Reddy, Y. N. V., Carter, R. E., Obokata, M., Redfield, M. M. & Borlaug, B. A. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 138, 861\u2013870 (2018). Derivation and validation of H2FPEF score for the diagnosis of HFpEF.","journal-title":"Circulation"},{"key":"540_CR153","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske, B. et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur. Heart J. 40, 3297\u20133317 (2019). HFA-PEFF diagnostic algorithm for the diagnosis of HFpEF.","journal-title":"Eur. Heart J."},{"key":"540_CR154","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2020","unstructured":"Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N. Engl. J. Med. 384, 117\u2013128 (2020).","journal-title":"N. Engl. J. Med."},{"key":"540_CR155","unstructured":"Lam, C. S. P., Shah, S. J. & Solomon, S. D. In: Braunwald\u2019s Heart Disease: International Edition. (eds Bonow, R.O. et al.) Ch. 51 (Elsevier Health Sciences, 2022)."},{"key":"540_CR156","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018689","volume":"10","author":"V Parcha","year":"2021","unstructured":"Parcha, V. et al. Obesity and serial NT-proBNP levels in guided medical therapy for heart failure with reduced ejection fraction: insights from the GUIDE-IT trial. J. Am. Heart Assoc. 10, e018689 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"540_CR157","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/ejhf.3036","volume":"25","author":"A Bayes-Genis","year":"2023","unstructured":"Bayes-Genis, A. et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the Heart Failure Association of the ESC. Eur. J. Heart Fail. 25, 1891\u20131898 (2023).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR158","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.amjcard.2013.05.061","volume":"112","author":"DH Katz","year":"2013","unstructured":"Katz, D. H. et al. Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. Am. J. Cardiol. 112, 1158\u20131164 (2013).","journal-title":"Am. J. Cardiol."},{"key":"540_CR159","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/ehf2.13705","volume":"9","author":"LH Lund","year":"2022","unstructured":"Lund, L. H. et al. Eligibility of patients with heart failure with preserved ejection fraction for sacubitril\/valsartan according to the PARAGON-HF trial. Esc. Heart Fail. 9, 164\u2013177 (2022).","journal-title":"Esc. Heart Fail."},{"key":"540_CR160","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","volume":"81","author":"BA Borlaug","year":"2023","unstructured":"Borlaug, B. A., Sharma, K., Shah, S. J. & Ho, J. E. Heart failure with preserved ejection fraction: JACC scientific statement. J. Am. Coll. Cardiol. 81, 1810\u20131834 (2023). JACC scientific statement providing updated guidance on the epidemiology, diagnosis and treatment of HFpEF.","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR161","doi-asserted-by":"publisher","first-page":"922398","DOI":"10.3389\/fcvm.2022.922398","volume":"9","author":"C Lau","year":"2022","unstructured":"Lau, C. et al. The role of cardiac magnetic resonance imaging in the assessment of heart failure with preserved ejection fraction. Front. Cardiovasc. Med. 9, 922398 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"540_CR162","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/ejhf.2601","volume":"24","author":"M Guazzi","year":"2022","unstructured":"Guazzi, M. et al. Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy \u2014 a clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology. Eur. J. Heart Fail. 24, 1327\u20131345 (2022).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR163","first-page":"87","volume":"9","author":"T Harada","year":"2022","unstructured":"Harada, T., Kagami, K., Kato, T., Ishii, H. & Obokata, M. Exercise stress echocardiography in the diagnostic evaluation of heart failure with preserved ejection fraction. J. Cardiovasc. Dev. Dis. 9, 87 (2022).","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"540_CR164","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/heartjnl-2017-312183","volume":"104","author":"A Bottle","year":"2018","unstructured":"Bottle, A. et al. Routes to diagnosis of heart failure: observational study using linked data in England. Heart 104, 600\u2013605 (2018).","journal-title":"Heart"},{"key":"540_CR165","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","volume":"141","author":"SJ Shah","year":"2020","unstructured":"Shah, S. J. et al. Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary. Circulation 141, 1001\u20131026 (2020). Working group meeting convened by the National Heart, Lung, and Blood Institute to discuss research gaps in HFpEF and prioritize directions over the next decade.","journal-title":"Circulation"},{"key":"540_CR166","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2174\/1573403X11309020006","volume":"9","author":"JE Blair","year":"2013","unstructured":"Blair, J. E., Huffman, M. & Shah, S. J. Heart failure in North America. Curr. Cardiol. Rev. 9, 128\u2013146 (2013).","journal-title":"Curr. Cardiol. Rev."},{"key":"540_CR167","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003613","volume":"10","author":"B Upadhya","year":"2017","unstructured":"Upadhya, B. et al. Effect of intensive blood pressure treatment on heart failure events in the systolic blood pressure reduction intervention trial. Circ. Heart Fail. 10, e003613 (2017).","journal-title":"Circ. Heart Fail."},{"key":"540_CR168","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jacc.2016.11.081","volume":"69","author":"A Pandey","year":"2017","unstructured":"Pandey, A. et al. Relationship between physical activity, body mass index, and risk of heart failure. J. Am. Coll. Cardiol. 69, 1129\u20131142 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR169","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2019.14231","volume":"322","author":"A Aminian","year":"2019","unstructured":"Aminian, A. et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA 322, 1271\u20131282 (2019).","journal-title":"JAMA"},{"key":"540_CR170","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"540_CR171","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/archinte.161.7.996","volume":"161","author":"J He","year":"2001","unstructured":"He, J. et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch. Intern. Med. 161, 996\u20131002 (2001).","journal-title":"Arch. Intern. Med."},{"key":"540_CR172","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire, D. K. et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 6, 148\u2013158 (2021).","journal-title":"JAMA Cardiol."},{"key":"540_CR173","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653\u2013662 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"540_CR174","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan, M. et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 400, 757\u2013767 (2022).","journal-title":"Lancet"},{"key":"540_CR175","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors, A. A. et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat. Med. 28, 568\u2013574 (2022).","journal-title":"Nat. Med."},{"key":"540_CR176","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer, M. A. et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131, 34\u201342 (2015).","journal-title":"Circulation"},{"key":"540_CR177","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon, S. D. et al. Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N. Engl. J. Med. 381, 1609\u20131620 (2019). Clinical trial investigating the effects of sacubitril-valsartan in individuals with HFpEF.","journal-title":"N. Engl. J. Med."},{"key":"540_CR178","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","volume":"141","author":"JJV McMurray","year":"2020","unstructured":"McMurray, J. J. V. et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction. Circulation 141, 338\u2013351 (2020).","journal-title":"Circulation"},{"key":"540_CR179","unstructured":"Entresto (Package Insert). Novartis https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/entresto.pdf (2015)."},{"key":"540_CR180","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41569-024-00996-1","volume":"21","author":"JY Chyou","year":"2024","unstructured":"Chyou, J. Y., Qin, H., Butler, J., Voors, A. A. & Lam, C. S. P. Sex-related similarities and differences in responses to heart failure therapies. Nat. Rev. Cardiol. 21, 498\u2013516 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"540_CR181","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","volume":"39","author":"JGF Cleland","year":"2018","unstructured":"Cleland, J. G. F. et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur. Heart J. 39, 26\u201335 (2018).","journal-title":"Eur. Heart J."},{"key":"540_CR182","doi-asserted-by":"publisher","first-page":"102376","DOI":"10.1016\/j.cpcardiol.2024.102376","volume":"49","author":"R Kaddoura","year":"2024","unstructured":"Kaddoura, R. et al. Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis. Curr. Probl. Cardiol. 49, 102376 (2024).","journal-title":"Curr. Probl. Cardiol."},{"key":"540_CR183","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jacc.2013.04.033","volume":"62","author":"DW Kitzman","year":"2013","unstructured":"Kitzman, D. W. et al. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. J. Am. Coll. Cardiol. 62, 584\u2013592 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR184","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jama.2015.17346","volume":"315","author":"DW Kitzman","year":"2016","unstructured":"Kitzman, D. W. et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 315, 36\u201346 (2016).","journal-title":"JAMA"},{"key":"540_CR185","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.jacc.2011.06.054","volume":"58","author":"F Edelmann","year":"2011","unstructured":"Edelmann, F. et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J. Am. Coll. Cardiol. 58, 1780\u20131791 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR186","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jama.2020.26812","volume":"325","author":"S Mueller","year":"2021","unstructured":"Mueller, S. et al. Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 325, 542\u2013551 (2021).","journal-title":"JAMA"},{"key":"540_CR187","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1161\/CIRCHEARTFAILURE.113.001229","volume":"7","author":"PB Adamson","year":"2014","unstructured":"Adamson, P. B. et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ. Heart Fail. 7, 935\u2013944 (2014).","journal-title":"Circ. Heart Fail."},{"key":"540_CR188","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0140-6736(21)01754-2","volume":"398","author":"J Lindenfeld","year":"2021","unstructured":"Lindenfeld, J. et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet 398, 991\u20131001 (2021).","journal-title":"Lancet"},{"key":"540_CR189","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/S0140-6736(22)00016-2","volume":"399","author":"SJ Shah","year":"2022","unstructured":"Shah, S. J. et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. Lancet 399, 1130\u20131140 (2022).","journal-title":"Lancet"},{"key":"540_CR190","first-page":"101203","volume":"2","author":"V Jagadeesan","year":"2023","unstructured":"Jagadeesan, V., Gray, W. A. & Shah, S. J. Atrial shunt therapy for heart failure: an update. J. Soc. Cardiovasc. Angiogr. Interv. 2, 101203 (2023).","journal-title":"J. Soc. Cardiovasc. Angiogr. Interv."},{"key":"540_CR191","unstructured":"National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03923673 (2022)."},{"key":"540_CR192","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003612","volume":"10","author":"BA Borlaug","year":"2017","unstructured":"Borlaug, B. A. et al. Percutaneous pericardial resection: a novel potential treatment for heart failure with preserved ejection fraction. Circ. Heart Fail. 10, e003612 (2017).","journal-title":"Circ. Heart Fail."},{"key":"540_CR193","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1001\/jamacardio.2022.5320","volume":"8","author":"M Infeld","year":"2023","unstructured":"Infeld, M. et al. Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: the myPACE randomized clinical trial. JAMA Cardiol. 8, 213\u2013221 (2023).","journal-title":"JAMA Cardiol."},{"key":"540_CR194","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh, T. A. et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 44, 3627\u20133639 (2023).","journal-title":"Eur. Heart J."},{"key":"540_CR195","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jacc.2016.05.019","volume":"68","author":"DW Kitzman","year":"2016","unstructured":"Kitzman, D. W. & Shah, S. J. The HFpEF obesity phenotype: the elephant in the room. J. Am. Coll. Cardiol. 68, 200\u2013203 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR196","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/s41366-020-0563-1","volume":"44","author":"TM Mandviwala","year":"2020","unstructured":"Mandviwala, T. M. et al. Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction. Int. J. Obes. 44, 1561\u20131567 (2020).","journal-title":"Int. J. Obes."},{"key":"540_CR197","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pcad.2022.11.013","volume":"78","author":"AW Tutor","year":"2023","unstructured":"Tutor, A. W., Lavie, C. J., Kachur, S., Milani, R. V. & Ventura, H. O. Updates on obesity and the obesity paradox in cardiovascular diseases. Prog. Cardiovasc. Dis. 78, 2\u201310 (2023).","journal-title":"Prog. Cardiovasc. Dis."},{"key":"540_CR198","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pcad.2024.01.003","volume":"82","author":"PL Alebna","year":"2024","unstructured":"Alebna, P. L. et al. Update on obesity, the obesity paradox, and obesity management in heart failure. Prog. Cardiovasc. Dis. 82, 34\u201342 (2024).","journal-title":"Prog. Cardiovasc. Dis."},{"key":"540_CR199","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/eurheartj\/ehad083","volume":"44","author":"JH Butt","year":"2023","unstructured":"Butt, J. H. et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. Eur. Heart J. 44, 1136\u20131153 (2023).","journal-title":"Eur. Heart J."},{"key":"540_CR200","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 389, 1069\u20131084 (2023). Clinical trial investigating the role of semaglutide in individuals with HFpEF and obesity.","journal-title":"N. Engl. J. Med."},{"key":"540_CR201","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","volume":"403","author":"J Butler","year":"2024","unstructured":"Butler, J. et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet 403, 1635\u20131648 (2024).","journal-title":"Lancet"},{"key":"540_CR202","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00059-022-05123-9","volume":"47","author":"A Deichl","year":"2022","unstructured":"Deichl, A., Wachter, R. & Edelmann, F. Comorbidities in heart failure with preserved ejection fraction. Herz 47, 301\u2013307 (2022).","journal-title":"Herz"},{"key":"540_CR203","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-020-01100-w","volume":"19","author":"A Halabi","year":"2020","unstructured":"Halabi, A., Sen, J., Huynh, Q. & Marwick, T. H. Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. Cardiovasc. Diabetol. 19, 124 (2020).","journal-title":"Cardiovasc. Diabetol."},{"key":"540_CR204","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","volume":"140","author":"SM Dunlay","year":"2019","unstructured":"Dunlay, S. M. et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update. Circulation 140, e294\u2013e324 (2019).","journal-title":"Circulation"},{"key":"540_CR205","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007475","volume":"7","author":"PB Sandesara","year":"2018","unstructured":"Sandesara, P. B. et al. Diastolic blood pressure and adverse outcomes in the TOPCAT (treatment of preserved cardiac function heart failure with an aldosterone antagonist) trial. J. Am. Heart Assoc. 7, e007475 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"540_CR206","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton, P. K. et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71, e13\u2013e115 (2018).","journal-title":"Hypertension"},{"key":"540_CR207","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/ejhf.445","volume":"18","author":"ED Unger","year":"2016","unstructured":"Unger, E. D. et al. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur. J. Heart Fail. 18, 103\u2013112 (2016).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR208","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","volume":"142","author":"FRM Causland","year":"2020","unstructured":"Causland, F. R. M. et al. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation 142, 1236\u20131245 (2020).","journal-title":"Circulation"},{"key":"540_CR209","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/ejhf.2122","volume":"23","author":"H Sugumar","year":"2021","unstructured":"Sugumar, H. et al. A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF-HFpEF. Eur. J. Heart Fail. 23, 785\u2013796 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR210","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/europace\/euaa420","volume":"23","author":"R Yamauchi","year":"2021","unstructured":"Yamauchi, R. et al. Catheter ablation for non-paroxysmal atrial fibrillation accompanied by heart failure with preserved ejection fraction: feasibility and benefits in functions and B-type natriuretic peptide. Europace 23, 1252\u20131261 (2021).","journal-title":"Europace"},{"key":"540_CR211","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/clc.23841","volume":"45","author":"G Gu","year":"2022","unstructured":"Gu, G. et al. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction: a meta-analysis. Clin. Cardiol. 45, 786\u2013793 (2022).","journal-title":"Clin. Cardiol."},{"key":"540_CR212","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1001\/jama.2020.23138","volume":"324","author":"D Kotecha","year":"2020","unstructured":"Kotecha, D. et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA 324, 2497\u20132508 (2020).","journal-title":"JAMA"},{"key":"540_CR213","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1016\/j.jacc.2014.03.034","volume":"63","author":"SJ Hwang","year":"2014","unstructured":"Hwang, S. J., Melenovsky, V. & Borlaug, B. A. Implications of coronary artery disease in heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 63, 2817\u20132827 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR214","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/ejhf.142","volume":"16","author":"D Rusinaru","year":"2014","unstructured":"Rusinaru, D. et al. Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction. Eur. J. Heart Fail. 16, 967\u2013976 (2014).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR215","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.hlc.2015.09.011","volume":"25","author":"T Arikawa","year":"2016","unstructured":"Arikawa, T. et al. Impact of obstructive sleep apnoea on heart failure with preserved ejection fraction. Heart Lung Circ. 25, 435\u2013441 (2016).","journal-title":"Heart Lung Circ."},{"key":"540_CR216","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.jacc.2017.01.041","volume":"69","author":"CM O\u2019Connor","year":"2017","unstructured":"O\u2019Connor, C. M. et al. Cardiovascular outcomes with minute ventilation \u2014 targeted adaptive servo-ventilation therapy in heart failure. J. Am. Coll. Cardiol. 69, 1577\u20131587 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR217","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2019-001012","volume":"6","author":"AL Beale","year":"2019","unstructured":"Beale, A. L. et al. Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Open Heart 6, e001012 (2019).","journal-title":"Open Heart"},{"key":"540_CR218","doi-asserted-by":"publisher","first-page":"I96","DOI":"10.1093\/eurheartjsupp\/suac080","volume":"24","author":"R Del Pinto","year":"2022","unstructured":"Del Pinto, R. & Ferri, C. Iron deficiency in heart failure: diagnosis and clinical implications. Eur. Heart J. Suppl. 24, I96\u2013I99 (2022).","journal-title":"Eur. Heart J. Suppl."},{"key":"540_CR219","doi-asserted-by":"publisher","unstructured":"von Haehling, S. et al. Iron deficiency in heart failure with preserved ejection fraction: rationale and design of the FAIR-HFpEF trial. Global Cardiol. https:\/\/doi.org\/10.4081\/cardio.2023.15 (2023).","DOI":"10.4081\/cardio.2023.15"},{"key":"540_CR220","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021494","volume":"10","author":"L Mooney","year":"2021","unstructured":"Mooney, L. et al. Impact of chronic obstructive pulmonary disease in patients with heart failure with preserved ejection fraction: insights from PARAGON\u2010HF. J. Am. Heart Assoc. 10, e021494 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"540_CR221","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235152","volume":"15","author":"WM Huang","year":"2020","unstructured":"Huang, W. M. et al. The role of pulmonary function in patients with heart failure and preserved ejection fraction: looking beyond chronic obstructive pulmonary disease. PLoS ONE 15, e0235152 (2020).","journal-title":"PLoS ONE"},{"key":"540_CR222","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1093\/eurheartj\/eht192","volume":"34","author":"NM Hawkins","year":"2013","unstructured":"Hawkins, N. M., Virani, S. & Ceconi, C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur. Heart J. 34, 2795\u20132807 (2013).","journal-title":"Eur. Heart J."},{"key":"540_CR223","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/JCN.0000000000000616","volume":"35","author":"R Meraz","year":"2020","unstructured":"Meraz, R. Medication nonadherence or self-care? Understanding the medication decision-making process and experiences of older adults with heart failure. J. Cardiovasc. Nurs. 35, 26\u201334 (2020).","journal-title":"J. Cardiovasc. Nurs."},{"key":"540_CR224","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijcard.2003.10.039","volume":"98","author":"PM Edmonds","year":"2005","unstructured":"Edmonds, P. M. et al. Patient descriptions of breathlessness in heart failure. Int. J. Cardiol. 98, 61\u201366 (2005).","journal-title":"Int. J. Cardiol."},{"key":"540_CR225","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1161\/CIR.0000000000001122","volume":"147","author":"V Sachdev","year":"2023","unstructured":"Sachdev, V. et al. Supervised exercise training for chronic heart failure with preserved ejection fraction: a scientific statement from the American Heart Association and American College of Cardiology. Circulation 147, e699\u2013e715 (2023).","journal-title":"Circulation"},{"key":"540_CR226","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/HRP.0000000000000162","volume":"26","author":"CM Celano","year":"2018","unstructured":"Celano, C. M., Villegas, A. C., Albanese, A. M., Gaggin, H. K. & Huffman, J. C. Depression and anxiety in heart failure: a review. Harv. Rev. Psychiatry 26, 175\u2013184 (2018).","journal-title":"Harv. Rev. Psychiatry"},{"key":"540_CR227","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamacardio.2021.0372","volume":"6","author":"SJ Greene","year":"2021","unstructured":"Greene, S. J. et al. Comparison of New York Heart Association class and patient-reported outcomes for heart failure with reduced ejection fraction. JAMA Cardiol. 6, 522\u2013531 (2021).","journal-title":"JAMA Cardiol."},{"key":"540_CR228","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/jamacardio.2021.0391","volume":"6","author":"PA Heidenreich","year":"2021","unstructured":"Heidenreich, P. A. The growing case for routine collection of patient-reported outcomes. JAMA Cardiol. 6, 497\u2013498 (2021).","journal-title":"JAMA Cardiol."},{"key":"540_CR229","unstructured":"Dolgin, M. & New York Heart Association Criteria Committee. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels 9th edn (Little, Brown, 1994)."},{"key":"540_CR230","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1161\/CIRCHEARTFAILURE.113.000359","volume":"6","author":"SM Joseph","year":"2013","unstructured":"Joseph, S. M. et al. Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction. Circ. Heart Fail. 6, 1139\u20131146 (2013).","journal-title":"Circ. Heart Fail."},{"key":"540_CR231","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/0002-8703(92)90986-6","volume":"124","author":"TS Rector","year":"1992","unstructured":"Rector, T. S. & Cohn, J. N. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am. Heart J. 124, 1017\u20131025 (1992).","journal-title":"Am. Heart J."},{"key":"540_CR232","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.120.050850","volume":"143","author":"I Johansson","year":"2021","unstructured":"Johansson, I. et al. Health-related quality of life and mortality in heart failure: the global congestive heart failure study of 23 000 patients from 40 countries. Circulation 143, 2129\u20132142 (2021).","journal-title":"Circulation"},{"key":"540_CR233","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1001\/jamacardio.2017.3983","volume":"2","author":"Y Pokharel","year":"2017","unstructured":"Pokharel, Y. et al. Association of serial kansas city cardiomyopathy questionnaire assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction: a secondary analysis of 2 randomized clinical trials. JAMA Cardiol. 2, 1315\u20131321 (2017).","journal-title":"JAMA Cardiol."},{"key":"540_CR234","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218983","volume":"14","author":"X Chen","year":"2019","unstructured":"Chen, X. et al. Quality of life and outcomes in heart failure patients with ejection fractions in different ranges. PLoS ONE\u00a014, e0218983 (2019).","journal-title":"PLoS ONE"},{"key":"540_CR235","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","volume":"76","author":"JA Spertus","year":"2020","unstructured":"Spertus, J. A., Jones, P. G., Sandhu, A. T. & Arnold, S. V. Interpreting the kansas city cardiomyopathy questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J. Am. Coll. Cardiol. 76, 2379\u20132390 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR236","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.001937","volume":"9","author":"EF Lewis","year":"2016","unstructured":"Lewis, E. F. et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ. Heart Fail. 9, e001937 (2016).","journal-title":"Circ. Heart Fail."},{"key":"540_CR237","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif, M. E. et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat. Med. 27, 1954\u20131960 (2021).","journal-title":"Nat. Med."},{"key":"540_CR238","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jacc.2023.01.016","volume":"81","author":"MS Duncan","year":"2023","unstructured":"Duncan, M. S. et al. Geographic variation in access to cardiac rehabilitation. J. Am. Coll. Cardiol. 81, 1049\u20131060 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR239","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.03.008","volume":"74","author":"RJ Thomas","year":"2019","unstructured":"Thomas, R. J. et al. Home-based cardiac rehabilitation: a scientific statement from the american association of cardiovascular and pulmonary rehabilitation, the American Heart Association, and the American College of Cardiology. J. Am. Coll. Cardiol. 74, 133\u2013153 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR240","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejhf.2894","volume":"25","author":"SD Anker","year":"2023","unstructured":"Anker, S. D. et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur. J. Heart Fail. 25, 936\u2013955 (2023).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR241","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2022.12","volume":"8","author":"JM Bilak","year":"2022","unstructured":"Bilak, J. M. et al. Microvascular dysfunction in heart failure with preserved ejection fraction: pathophysiology, assessment, prevalence and prognosis. Card. Fail. Rev. 8, e24 (2022).","journal-title":"Card. Fail. Rev."},{"key":"540_CR242","doi-asserted-by":"publisher","first-page":"H1364","DOI":"10.1152\/ajpheart.00004.2014","volume":"306","author":"DW Kitzman","year":"2014","unstructured":"Kitzman, D. W. et al. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. Am. J. Physiol. Heart Circ. Physiol. 306, H1364\u2013H1370 (2014).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"540_CR243","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijcard.2016.07.135","volume":"222","author":"T Bekfani","year":"2016","unstructured":"Bekfani, T. et al. Sarcopenia in patients with heart failure with preserved ejection fraction: impact on muscle strength, exercise capacity and quality of life. Int. J. Cardiol. 222, 41\u201346 (2016).","journal-title":"Int. J. Cardiol."},{"key":"540_CR244","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1161\/CIRCULATIONAHA.117.031608","volume":"137","author":"AU Fayyaz","year":"2018","unstructured":"Fayyaz, A. U. et al. Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation 137, 1796\u20131810 (2018).","journal-title":"Circulation"},{"key":"540_CR245","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jchf.2016.03.001","volume":"4","author":"TP Olson","year":"2016","unstructured":"Olson, T. P., Johnson, B. D. & Borlaug, B. A. Impaired pulmonary diffusion in heart failure with preserved ejection fraction. JACC Heart Fail. 4, 490\u2013498 (2016).","journal-title":"JACC Heart Fail."},{"key":"540_CR246","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s12265-017-9736-2","volume":"10","author":"JA Chirinos","year":"2017","unstructured":"Chirinos, J. A. Deep phenotyping of systemic arterial hemodynamics in HFpEF (part 2): clinical and therapeutic considerations. J. Cardiovasc. Transl. Res. 10, 261\u2013274 (2017).","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"540_CR247","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.amjcard.2015.06.038","volume":"116","author":"DA Klein","year":"2015","unstructured":"Klein, D. A. et al. Association of chronic kidney disease with chronotropic incompetence in heart failure with preserved ejection fraction. Am. J. Cardiol. 116, 1093\u20131100 (2015).","journal-title":"Am. J. Cardiol."},{"key":"540_CR248","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/ejhf.821","volume":"19","author":"I L\u00f6fman","year":"2017","unstructured":"L\u00f6fman, I., Szummer, K., Dahlstr\u00f6m, U., Jernberg, T. & Lund, L. H. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur. J. Heart Fail. 19, 1606\u20131614 (2017).","journal-title":"Eur. J. Heart Fail."},{"key":"540_CR249","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/JCN.0000000000000711","volume":"37","author":"KM Faulkner","year":"2022","unstructured":"Faulkner, K. M. et al. Factors associated with cognitive impairment in heart failure with preserved ejection fraction. J. Cardiovasc. Nurs. 37, 17\u201330 (2022).","journal-title":"J. Cardiovasc. Nurs."},{"key":"540_CR250","doi-asserted-by":"publisher","DOI":"10.1002\/alz.046641","volume":"16","author":"CE Hugenschmidt","year":"2020","unstructured":"Hugenschmidt, C. E. et al. Heart failure with preserved ejection fraction (HFpEF) is associated with cognitive impairment and reduced brain volume. Alzheimers Dement. 16, e046641 (2020).","journal-title":"Alzheimers Dement."},{"key":"540_CR251","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008992","volume":"7","author":"MC Johansen","year":"2018","unstructured":"Johansen, M. C. et al. Associations of echocardiography markers and vascular brain lesions: the ARIC study. J. Am. Heart Assoc. 7, e008992 (2018).","journal-title":"J. Am. Heart Assoc."}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-024-00540-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-024-00540-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-024-00540-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T08:02:35Z","timestamp":1723622555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-024-00540-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":251,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["540"],"URL":"https:\/\/doi.org\/10.1038\/s41572-024-00540-y","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"15 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.D.\u2019s spouse is employed by and holds stock in iRhythm Technologies. L.H.L. is supported by Karolinska Institutet, the Swedish Research Council (grant 523-2014-2336), the Swedish Heart Lung Foundation (grants 20150557, 20190310) and the Stockholm County Council (grants 20170112, 20190525). L.H.L. is advisor\/consultant for AstraZeneca, Novartis, Bayer, Vifor Pharma, Pharmacosmos, Merck\/MSD, Respicardia, and Medscape; receives honoraria\/lecture fees from AstraZeneca, Novartis, Vifor Pharma, Bayer, Medscape and Radcliffe Cardiology; receives research grants from AstraZeneca, Novartis, Boehringer Ingelheim, Vifor Pharma and Pharmacosmos; and has stock ownership for AnaCardio. S.J.S. is supported by research grants from the U.S. National Institutes of Health (U54 HL160273; R01 HL140731; and R01 HL149423); has received research funding from AstraZeneca, Corvia and Pfizer; and has received consulting fees from Abbott, Alleviant, Amgen, Aria CV, AstraZeneca, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, BridgeBio, Bristol Myers Squibb, Corvia, Cytokinetics, Edwards Lifesciences, Eidos, Imara, Impulse Dynamics, Intellia, Ionis, Lilly, Merck, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sardocor, Shifamed, Tenax, Tenaya and Ultromics. S.S. has received research grants from Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos\/Bridgebio, Gossamer, GSK, Ionis, Lilly, National Institutes of Health\/National Heart, Lung, and Blood Institute, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, and US2.AI and has consulted for Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, GSK, Lilly, Novartis, Roche, Theracos, Quantum Genomics, Tenaya, Sanofi Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, and Valo. C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Novo Nordisk and Roche Diagnostics; has served as consultant or on the Advisory Board\/Steering Committee\/Executive Committee for Alleviant Medical, Allysta Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, CPC Clinical Research, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape\/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc., Quidel Corporation, Radcliffe Group Ltd., Recardio Inc., ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. The\u00a0remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}